Iovance Biotherapeutics (IOVA) vs Rhythm Pharmaceuticals (RYTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Iovance Biotherapeutics (IOVA) has outperformed Rhythm Pharmaceuticals (RYTM) over the past year, gaining 492.4% versus a loss of 11.4%. Over five years, RYTM leads with a +682.1% price change compared with -51.5% for IOVA. Rhythm Pharmaceuticals is the larger company by market cap ($6.09 billion vs $5.85 billion), about 1.0 times the size, while Iovance Biotherapeutics is growing revenue faster (+60.6% vs +45.8%).
Rhythm Pharmaceuticals converts more of its revenue into profit, with a net margin of -103.6% versus -148.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IOVA | RYTM |
|---|---|---|
| Share price | $12.92 | $88.45 |
| Market cap | $5.85B | $6.09B |
| 1-day change | -0.35% | -2.56% |
| YTD return | +373.08% | -17.37% |
| 1-year return | +492.43% | -11.40% |
| 5-year return | -51.47% | +682.05% |
| EPS (TTM) | $-0.69 | $-3.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $263.50M | $189.76M |
| Revenue growth (YoY) | +60.60% | +45.83% |
| Net income (latest FY) | $-390.98M | $-196.54M |
| Gross margin | 34.28% | 89.73% |
| Operating margin | -153.08% | -101.19% |
| Net margin | -148.38% | -103.57% |
| 52-week high | $15.30 | $122.20 |
| 52-week low | $1.76 | $74.50 |
| Distance from 52-week high | -15.59% | -27.62% |
| Analyst consensus | buy | none |
| Avg. price target upside | -0.89% | +56.69% |
| Average volume | 17.85M | 646.31K |
| Shares outstanding | 452.97M | 68.85M |
| Employees | 975 | 414 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IOVA has outperformed RYTM by 503.8 percentage points over the past year.
- Rhythm Pharmaceuticals is more profitable, keeping -103.6 cents of every revenue dollar as net income versus -148.4 cents for Iovance Biotherapeutics.
- Iovance Biotherapeutics grew revenue faster in its latest fiscal year (+60.60% vs +45.83%).
About Iovance Biotherapeutics
IOVA stock →Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 975 employees
About Rhythm Pharmaceuticals
RYTM stock →Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 414 employees
IOVA vs RYTM FAQ
Which is bigger, Iovance Biotherapeutics or Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals (RYTM) is larger, with a market capitalization of $6.09B compared with $5.85B for Iovance Biotherapeutics (IOVA).
Which stock has performed better over the past year, IOVA or RYTM?
IOVA returned +492.43% over the past 12 months, compared with -11.40% for RYTM (price return, excluding dividends). Past performance does not predict future results.
Are Iovance Biotherapeutics and Rhythm Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Iovance Biotherapeutics and Biotechnology: Pharmaceutical Preparations for Rhythm Pharmaceuticals.